Provided by Tiger Trade Technology Pte. Ltd.

Immunovant, Inc.

26.60
+0.24000.91%
Post-market: 26.700.1000+0.38%17:56 EST
Volume:719.67K
Turnover:19.03M
Market Cap:5.41B
PE:-9.93
High:26.78
Open:26.17
Low:25.76
Close:26.36
52wk High:27.92
52wk Low:12.72
Shares:203.53M
Float Shares:89.02M
Volume Ratio:0.70
T/O Rate:0.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.6799
EPS(LYR):-2.7303
ROE:-69.35%
ROA:-41.33%
PB:5.49
PE(LYR):-9.74

Loading ...

Immunovant Inc. to Announce Third Quarter Financial Results and Business Update

Reuters
·
Jan 26

Roivant Sciences President and Immunovant CEO Eric Venker Reports Disposal of Common Shares

Reuters
·
Jan 15

Immunovant price target raised to $22 from $16 at Truist

TIPRANKS
·
Jan 08

Immunovant Raised to Outperform From Peer Perform by Wolfe Research

Dow Jones
·
Jan 06

Roivant Sciences President and Immunovant CEO Eric Venker Reports Disposal of Common Shares

Reuters
·
Dec 30, 2025

Immunovant (IMVT): Reassessing Valuation After a $550 Million Follow-On Equity Raise

Simply Wall St.
·
Dec 21, 2025

Immunovant (IMVT) Is Up 14.0% After $550 Million Follow-On Backed By Roivant Sciences - What's Changed

Simply Wall St.
·
Dec 15, 2025

Immunovant (IMVT): Reassessing Valuation After $550 Million Follow-On Offering for IMVT-1402 Launch

Simply Wall St.
·
Dec 12, 2025

Immunovant Inc - Files for Offering of 26,200,000 Shares of Common Stock - SEC Filing

THOMSON REUTERS
·
Dec 12, 2025

Roivant Sciences President and Immunovant CEO Eric Venker Reports Disposal of Common Shares

Reuters
·
Dec 12, 2025

Roivant Signals Major Pipeline Momentum With Accelerated Timelines

Benzinga_recent_news
·
Dec 12, 2025

Roivant Sciences Fast-Tracks Key Drug Development Programs

MT Newswires Live
·
Dec 11, 2025

Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Thursday as Oracle Results Sour Investor Mood

MT Newswires Live
·
Dec 11, 2025

Immunovant Inc - Offers 26.2 Mln Shares at $21.00 per Share

THOMSON REUTERS
·
Dec 11, 2025

Press Release: Immunovant Announces Pricing of $550 Million Common Stock Financing

Dow Jones
·
Dec 11, 2025

Immunovant (IMVT): Assessing Valuation Following R&D Leadership Restructuring and CMO Departure

Simply Wall St.
·
Nov 26, 2025

Immunovant Chief Medical Officer Michael Geffner Steps Down

MT Newswires Live
·
Nov 21, 2025

Immunovant Chief Medical Officer Michael Geffner Departs Amid R&D Restructuring

Reuters
·
Nov 21, 2025

J.P. Morgan Sticks to Their Buy Rating for Immunovant (IMVT)

TIPRANKS
·
Nov 21, 2025

H.C. Wainwright Reaffirms Their Buy Rating on Immunovant (IMVT)

TIPRANKS
·
Nov 15, 2025